FIELD: medicine.
SUBSTANCE: present group of inventions refers to retinitis pigmentosa treatment. Method of treating retinitis pigmentosa in a mammal, comprising administering to a mammal a therapeutically effective amount of a dose of N-acetylcysteine amide (NACA) of 100, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1000, 2500, 5000, 7500 or 10,000 mg per dose. Method of treating retinitis pigmentosa, involving identification of a person in need of treating retinitis pigmentosa, at least one of scotopic or photopic electro-retinogram and administering to a human a therapeutically effective amount of a solid dosage form of N-acetylcysteine amide (NACA) sufficient for treating retinitis pigmentosa of 100, 150, 300, 333, 400, 500, 600, 700, 750, 800, 900, 1000, 2500, 5000, 7500 or 10,000 mg per dose.
EFFECT: above described methods are effective for treating retinitis pigmentosa, doses higher than 100 mg of NACA are well tolerated.
17 cl, 4 dwg
